We Offer Worldwide Shipping
Login Wishlist

Vitamin K1

$93

  • Brand : BIOFRON

  • Catalogue Number : BF-V2008

  • Specification : 98%

  • CAS number : 84-80-0

  • Formula : C31H46O2

  • Molecular Weight : 450.7

  • PUBCHEM ID : 5284607

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-V2008

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

450.7

Appearance

Yellow liquid

Botanical Source

synthesis

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C

Synonyms

KONAKION/Rac-Phytonadione-D7/Phylloquinone-d3/VITAMIN K1 (PHYTONADIONE)/Veda K1/2-Methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]-1,4-naphthoquinone/Kephton/Antihemorrhagic vitamin/1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-/2-METHYL-3-PHYTYL-1,4-NAPHTHOQUINONE/2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dion/2',3'-trans-Vitamin K1/AQUAMEPHYTON/Combinal K1/Orakay/1,4-NAPHTHALENEDIONE,2-METHYL-3-[(2E,7R,11R)-3,7,11,15-TETRAMETHYL-2-HEXADECEN-1-YL]-/2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphtalene-1,4-dione/Vitamin K1/Veta K1/[R-[R*,R*-(E)]]-2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione/VITAMIN K1-[2H7] (PHYTONADIONE)/Phyllochinonu/Phytonadione, K1/1,4-naphthalenedione, 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl]/VITAMIN K/PHYLLOQUINONE/phytomenadione/Kaywan/2-Methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalen-1,4-dion/2-Methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-naphthoquinone/1,4-Naphthalenedione, 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]-/2-Methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione/Aqua mephyton/vitamin K1 quinone/Vitamin K1 (VAN)/Kativ N/K-Ject/VITAMIN K1/Synthex P/2',3'-t/Phytylmenadione/kativn/Mono-kay/PHYTONADIONE/Kinadion/Vitamin- K1/Phylloquinone (8CI)/PHYTOMENADIONE, BP STANDARD

IUPAC Name

2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione

Density

1.0±0.1 g/cm3

Solubility

Methanol; Chloroform; Ethyl Acetate

Flash Point

200.4±27.1 °C

Boiling Point

546.4±50.0 °C at 760 mmHg

Melting Point

−20 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2936290000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:84-80-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31862867

Abstract

Vitamin K is required for the ɣ-carboxylation of specific glutamic acid residues within the Gla domain of the 17 vitamin K-dependent proteins (VKDPs). The timely detection and correction of vitamin K deficiency can protect against bleeding. Vitamin K also plays a role in bone metabolism and vascular calcification. Patients at increased risk of vitamin K deficiency include those with a restricted diet or malnutrition, lipid malabsorption, cancer, renal disease, neonates and the elderly. Coagulation assays such as the prothrombin time have been used erroneously as indicators of vitamin K status, lacking sufficient sensitivity and specificity for this application. The measurement of phylloquinone (K1) in serum is the most commonly used marker of vitamin K status and reflects abundance of the vitamin. Concentrations <0.15 µg/L are indicative of deficiency. Disadvantages of this approach include exclusion of the other vitamin K homologues and interference from recent dietary intake. The cellular utilisation of vitamin K is determined through measurement of the prevalence of undercarboxylated VKDPs. Most commonly, undercarboxylated prothrombin (Protein Induced by Vitamin K Absence/antagonism, PIVKA-II) is used (reference range 17.4-50.9 mAU/mL (Abbott Architect), providing a retrospective indicator of hepatic vitamin K status. Current clinical applications of PIVKA-II include supporting the diagnosis of vitamin K deficiency bleeding of the newborn, monitoring exposure to vitamin K antagonists, and when used in combination with α-fetoprotein, as a diagnostic marker of hepatocellular carcinoma. Using K1 and PIVKA-II in tandem is an approach that can be used successfully for many patient cohorts, providing insight into both abundance and utilisation of the vitamin.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

KEYWORDS

bleeding disorders; bone; calcium metabolism; coagulation; nutrition

Title

Laboratory assessment of vitamin K status.

Author

Card DJ1, Gorska R1, Harrington DJ2,3.

Publish date

2020 Feb

PMID

31749617

Abstract

AIMS:
Different kinds of vitamins can be used as promising candidates to mitigate the structural changes of proteins and associated cytotoxicity stimulated by NPs. Therefore, the structural changes of α-syn molecules and their associated cytotoxicity in the presence of SWCNTs either alone or co-incubated with vitamin K1 were studied by spectroscopic, bioinformatical, and cellular assays.

METHODS:
Intrinsic and ThT fluorescence, CD, and Congo red absorption spectroscopic approaches as well as TEM investigation, molecular docking, and molecular dynamics were used to explore the protective effect of vitamin K1 on the structural changes of α-syn induced by SWCNTs. The cytotoxicity of α-syn/SWCNTs co-incubated with vitamin K1 against SH-SY5Y cells was also carried out by MTT, LDH, and caspase-3 assays.

RESULTS:
Fluorescence spectroscopy showed that vitamin K1 has a significant effect in reducing SWCNT-induced fluorescence quenching and aggregation of α- syn. CD, Congo red adsorption, and TEM investigations determined that co-incubation of α- syn with vitamin K1 inhibited the propensity of α-syn into the structural changes and amorphous aggregation in the presence of SWCNT. Docking studies determined the occupation of preferred docked site of SWCNT by vitamin K1 on α- syn conformation. A molecular dynamics study also showed that vitamin K1 reduced the structural changes of α- syn induced by SWCNT. Cellular data exhibited that the cytotoxicity of α- syn co-incubated with vitamin K1 in the presence of SWCNTs is less than the outcomes obtained in the absence of the vitamin K1.

CONCLUSION:
It may be concluded that vitamin K1 decreases the propensity of α- syn aggregation in the presence of SWCNTs and induction of cytotoxicity.

© 2019 Naskhi et al.

KEYWORDS

aggregation; cytotoxicity; single-walled carbon nanotube; vitamin K1; α- Syn

Title

Vitamin K1 As A Potential Molecule For Reducing Single-Walled Carbon Nanotubes-Stimulated α-Synuclein Structural Changes And Cytotoxicity.

Author

Naskhi A#1, Jabbari S#1, Othman GQ2, Aziz FM3, Salihi A3,4, Sharifi M5, Sari S1, Akhtari K6, Abdulqadir SZ3, Alasady AA7, Abou-Zied OK8, Hasan A9,10, Falahati M5.

PMID

31173816

Abstract

The effect of menaquinone-7 isolated from cheonggukjang was comparatively investigated with vitamin K1 and menaquinone-4 on cell differentiation and mineralization of the osteoblastic cell line MC3T3-E1. Results indicated that all vitamin K species significantly increased MC3T3-E1 cell proliferation, cellular alkaline phosphatase activity, osteocalcin synthesis, and calcium deposition in a dose-dependent manner. Menaquinone-4 and menaquinone-7 had more potent effects on calcium deposition than vitamin K1, and their effects were only partly reduced by warfarin (γ-carboxylation inhibitor) treatment, while warfarin abolished the induction activity of vitamin K1 on calcification. This suggests that vitamin K1 and K2 (menaquinone-4 & menaquinone-7) may have different mechanisms in stimulating osteoblast mineralization. In addition, the mRNA expression ratio of osteoprotegerin and the receptor activator of nuclear factor-kB ligand was also dramatically increased by treatment with vitamin K1 (62%), menaquinone-4 (247%), and menaquinone-7 (329%), suggesting that vitamin K may suppress the formation of osteoclast by up-regulating the ratio of osteoprotegerin/receptor activator of nuclear factor-kB ligand in osteoblasts. These results provide compelling evidence that vitamin K1, menaquinone-4, and menaquinone-7 all can promote bone health, which might be associated with elevations in the osteoprotegerin/receptor activator of nuclear factor-kB ligand ratio.

Copyright © 2019 Elsevier Ltd. All rights reserved.

KEYWORDS

Menaquinone; OPG/RANKL; Osteoblasts; Proliferation; Vitamin K

Title

A comparatively study of menaquinone-7 isolated from Cheonggukjang with vitamin K1 and menaquinone-4 on osteoblastic cells differentiation and mineralization.

Author

Wu WJ1, Gao H2, Jin JS3, Ahn BY4.

Publish date

2019 Sep


Description :

Vitamin K1 a fat-soluble, naturally occurring vitamin required for blood coagulation and bone and vascular metabolism.